Sudeep Pharma’s Rs 895-crore IPO enters its final bidding day with strong overall demand, led by robust NII and retail participation. Despite a softening grey-market premium, subscription momentum remains healthy. Backed by diversified excipient capabilities, steady financial growth and anchor interest, the company is positioned favourably as it approaches allotment and listing. Source link India News Sebi mulls simplifying paperwork,… Dutch bank ABN Amro to cut 5,200… Bangladeshi national booked in… Night curfew clamped along… Stock Market Zen Technologies wins contract… Your Next Trip to Shop at Ikea… FBI seeks to interview Sen. Mark… Inside one US company's… Space…